greeksoup/ stock research

Thermo Fisher Scientific (TMO) Q1 FY2025 earnings: revenue $10.4 billion, up 0.2% on the year

Thermo Fisher Scientific Inc. (TMO) reported revenue of $10.4 billion for Q1 FY2025, the quarter ended 29 March 2025, up 0.2% on the same quarter a year earlier. Net income was $1.5 billion, up 13.5% on the year, and diluted earnings per share $3.98. The figures are the company's own, from the 10-Q it filed with the SEC on 2 May 2025.

Revenue
$10.4 billion
+0.2% on the year · -9.0% on the quarter
Q2 FY2023Q1 FY2025
Operating margin
16.6%
16.1% a year earlier
Q2 FY2023Q1 FY2025
Net income
$1.5 billion
+13.5% on the year · -17.6% on the quarter
Q2 FY2023Q1 FY2025
Diluted EPS
$3.98
+15.0% on the year · -16.7% on the quarter
Q2 FY2023Q1 FY2025

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ1 FY2025Q4 FY2024Q1 FY2024On the quarterOn the yearLast 8 quarters
Revenue10,36411,39510,345-9.0%+0.2%
Cost of revenue6,1296,5736,140-6.8%-0.2%
Gross profit4,2354,8224,205-12.2%+0.7%
Gross margin40.9%42.3%40.6%
Research and development342374331-8.6%+3.3%
Selling, general and administrative2,0782,2032,183-5.7%-4.8%
Operating income1,7162,0161,663-14.9%+3.2%
Operating margin16.6%17.7%16.1%
Interest expense303317363-4.4%-16.5%
Pre-tax income1,6201,9411,589-16.5%+2.0%
Income tax95.0149281-36.2%-66.2%
Effective tax rate5.9%7.7%17.7%
Net income1,5071,8291,328-17.6%+13.5%
Net margin14.5%16.1%12.8%
Diluted EPS$3.98$4.78$3.46-16.7%+15.0%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ1 FY2025Q4 FY2024Q1 FY2024On the quarterOn the yearLast 8 quarters
Operating cash flow7233,2901,251-78.0%-42.2%
Capital expenditure362480347-24.6%+4.3%
Free cash flow3612,810904-87.2%-60.1%
Free cash flow margin3.5%24.7%8.7%
Cash from investing-52720.0-2,030
Cash from financing-102-3,666-1,821
Depreciation and amortisation705742836-5.0%-15.7%
Share-based compensation75.079.070.0-5.1%+7.1%
Buybacks2,0001,0003,000+100.0%-33.3%
Dividends paid1491491350.0%+10.4%
Dividend per share$0.43n/a$0.39+10.3%
Diluted shares, weighted379m383m384m-1.0%-1.3%
Shares outstanding at period end377m377m382m+0.1%-1.1%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ1 FY2025Q4 FY2024Q1 FY2024On the quarterOn the yearLast 8 quarters
Shareholders' equity49,39049,58445,516-0.4%+8.5%
Non-controlling interest-33.0-33.0-12.0
Redeemable equity128120119+6.7%+7.6%
Debt34,18931,27535,608+9.3%-4.0%
Operating lease liabilitiesn/a1,239n/a
Other liabilities15,36715,13615,864+1.5%-3.1%
Total liabilities and equity99,04197,32197,095+1.8%+2.0%
Fixed assets9,3319,3069,324+0.3%+0.1%
Goodwill46,49345,85343,843+1.4%+6.0%
Intangible assets15,32315,53316,048-1.4%-4.5%
Investments1,8131,5611,751+16.1%+3.5%
Cash and equivalents4,1344,0095,499+3.1%-24.8%
Receivables8,4558,1917,931+3.2%+6.6%
Inventory5,2244,9785,133+4.9%+1.8%
Other assets8,2687,8907,566+4.8%+9.3%
Total assets99,04197,32197,095+1.8%+2.0%

Questions

What was Thermo Fisher Scientific's revenue in Q1 FY2025?

Thermo Fisher Scientific (TMO) reported revenue of $10.4 billion for Q1 FY2025, the quarter ended 29 March 2025, up 0.2% on the same quarter a year earlier.

How much did Thermo Fisher Scientific earn in Q1 FY2025?

Net income for Q1 FY2025 was $1.5 billion, up 13.5% on the year, and diluted earnings per share $3.98.

When did Thermo Fisher Scientific report Q1 FY2025 results?

Thermo Fisher Scientific filed its 10-Q for the quarter ended 29 March 2025 with the SEC on 2 May 2025.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue10,70211,81810,97010,67711,45010,71010,68710,57410,88610,34510,54110,59811,39510,36410,85511,12212,21511,00511,99412,137
Cost of revenue5,4486,3546,3716,3756,8446,5706,4366,2586,4936,1406,1946,2706,5736,1296,4466,5397,2046,5757,1127,006
Gross profit5,2545,4644,5994,3024,6064,1404,2514,3164,3934,2054,3474,3284,8224,2354,4094,5835,0114,4304,8825,131
Gross margin49%46%42%40%40%39%40%41%40%41%41%41%42%41%41%41%41%40%41%42%
R&D392364365351391346345319327331339346374342352346357336364348
SG&A2,2782,2772,2092,2082,2992,1192,1452,0492,1322,1832,1112,0982,2032,0782,1402,1622,3522,1812,3332,321
Operating income2,5382,8212,0011,7101,8611,5631,5781,8641,8541,6631,8201,8382,0161,7161,8341,9412,2551,8632,0872,263
Operating margin24%24%18%16%16%15%15%18%17%16%17%17%18%17%17%17%18%17%17%19%
Interest expense161136148173269300326359390363354356317303404347365354401417
Pre-tax income1,8682,5401,9171,6011,7771,3631,4301,7651,7401,5891,7651,7421,9411,6201,7091,8262,1531,7341,9242,088
Tax rate11%12%10%2%10%3%4%3%8%18%7%6%8%6%5%11%7%4%9%17%
Net income1,6582,2151,6641,4951,5761,2891,3611,7151,6301,3281,5481,6301,8291,5071,6171,6161,9641,6511,7361,721
Net margin15%19%15%14%14%12%13%16%15%13%15%15%16%15%15%15%16%15%14%14%
Diluted EPS$4.18$5.61$4.22$3.79$4.01$3.32$3.51$4.42$4.20$3.46$4.04$4.25$4.78$3.98$4.28$4.27$5.21$4.43$4.68$4.64
Operating cash flow2,4572,2021,5281,9373,4877291,5402,4143,7231,2511,9602,1663,2907231,3992,2393,4571,1922,1252,550
Capital expenditure831640506547550458284332405347301272480362294404465376450437
Free cash flow1,6261,5621,0221,3902,9372711,2562,0823,3189041,6591,8942,8103611,1051,8352,9928161,6752,113
Buybacks0.02,0000.00.01,0003,0000.00.00.03,0000.00.01,0002,0000.096337.03,0001,0000.0
Dividends paid103103117118117117135135136135149150149149162163162162175174
Shares outstanding391m391m392m392m385m386m386m386m381m382m382m383m377m377m378m376m371m372m370m371m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 29 March 2025, filed 2 May 2025: the filing.